| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.599 | 0.004 | 0.599 | p38 MAP kinase inhibitor | 0.24 0.01 DBMET03538 0.205 0.013 DBMET03219 | ||
| 0.525 | 0.02 | 0.525 | GABA C receptor rho-3 antagonist | 0.402 0.06 DBMET03538 0.461 0.038 DBMET03219 | ||
| 0.518 | 0.026 | 0.518 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.397 0.103 DBMET03538 0.511 0.029 DBMET03219 | ||
| 0.464 | 0.045 | 0.653 | 5 Hydroxytryptamine release inhibitor | 0.39 0.084 DBMET03538 0.653 0.006 DBMET03219 | DBMET03219 | |
| 0.441 | 0.029 | 0.441 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.168 0.123 DBMET03538 0.331 0.056 DBMET03219 | ||
| 0.372 | 0.025 | 0.41 | Peroxidase inhibitor | 0.348 0.029 DBMET03538 0.41 0.019 DBMET03219 | DBMET03219 | |
| 0.348 | 0.007 | 0.357 | Glutamate receptor antagonist | 0.244 0.016 DBMET03538 0.357 0.007 DBMET03219 | DBMET03219 | |
| 0.333 | 0.005 | 0.419 | Ferrochelatase inhibitor | 0.225 0.017 DBMET03538 0.419 0.003 DBMET03219 | DBMET03219 | |
| 0.385 | 0.083 | 0.581 | Histamine release inhibitor | 0.445 0.052 DBMET03538 0.581 0.012 DBMET03219 | DBMET03219 | |
| 0.315 | 0.037 | 0.343 | Anticonvulsant | 0.343 0.03 DBMET03538 0.201 0.082 DBMET03219 | DBMET03538 | |
| 0.316 | 0.044 | 0.316 | Pyruvate kinase inhibitor | 0.213 0.074 DBMET03219 | ||
| 0.311 | 0.052 | 0.347 | Insulysin inhibitor | 0.276 0.074 DBMET03538 0.347 0.035 DBMET03219 | DBMET03219 | |
| 0.273 | 0.02 | 0.273 | Nitric-oxide synthase stimulant | 0.266 0.023 DBMET03538 0.201 0.087 DBMET03219 | ||
| 0.337 | 0.094 | 0.46 | Antiobesity | 0.352 0.086 DBMET03538 0.46 0.047 DBMET03219 | DBMET03219 | |
| 0.268 | 0.025 | 0.268 | Cytidine deaminase inhibitor | 0.192 0.052 DBMET03538 0.236 0.033 DBMET03219 | ||
| 0.275 | 0.038 | 0.317 | RNA-directed DNA polymerase inhibitor | 0.317 0.029 DBMET03538 0.269 0.04 DBMET03219 | DBMET03538 | |
| 0.352 | 0.116 | 0.462 | Calcium channel L-type activator | 0.462 0.045 DBMET03538 0.39 0.088 DBMET03219 | DBMET03538 | |
| 0.258 | 0.023 | 0.258 | Histone acetyltransferase inhibitor | 0.173 0.109 DBMET03538 0.234 0.033 DBMET03219 | ||
| 0.249 | 0.013 | 0.392 | UDP-glucose 4-epimerase inhibitor | 0.371 0.007 DBMET03538 0.392 0.006 DBMET03219 | DBMET03219 | |
| 0.281 | 0.05 | 0.382 | Cyclic AMP phosphodiesterase inhibitor | 0.286 0.048 DBMET03538 0.382 0.019 DBMET03219 | DBMET03219 | |
| 0.247 | 0.017 | 0.247 | 5 Hydroxytryptamine 3E antagonist | 0.194 0.073 DBMET03538 0.181 0.104 DBMET03219 | ||
| 0.233 | 0.009 | 0.472 | Porphobilinogen synthase inhibitor | 0.374 0.004 DBMET03538 0.472 0.004 DBMET03219 | DBMET03219 | |
| 0.306 | 0.086 | 0.306 | Calcium channel activator | 0.27 0.124 DBMET03538 0.285 0.107 DBMET03219 | ||
| 0.222 | 0.008 | 0.222 | Glutamate (mGluR) antagonist | 0.101 0.034 DBMET03538 0.136 0.02 DBMET03219 | ||
| 0.215 | 0.007 | 0.215 | Glutamate (mGluR group I) antagonist | 0.083 0.036 DBMET03538 0.099 0.027 DBMET03219 | ||
| 0.325 | 0.118 | 0.475 | Antibacterial | 0.369 0.091 DBMET03538 0.475 0.048 DBMET03219 | DBMET03219 | |
| 0.349 | 0.146 | 0.432 | Caspase 9 stimulant | 0.432 0.093 DBMET03538 0.277 0.22 DBMET03219 | DBMET03538 | |
| 0.256 | 0.063 | 0.355 | DNA synthesis inhibitor | 0.348 0.031 DBMET03538 0.355 0.029 DBMET03219 | DBMET03219 | |
| 0.26 | 0.068 | 0.279 | Gastrin inhibitor | 0.226 0.11 DBMET03538 0.279 0.049 DBMET03219 | DBMET03219 | |
| 0.262 | 0.07 | 0.348 | Interleukin agonist | 0.348 0.03 DBMET03538 0.315 0.041 DBMET03219 | DBMET03538 | |
| 0.225 | 0.036 | 0.225 | Heat shock protein 90 alpha antagonist | 0.139 0.099 DBMET03538 0.221 0.038 DBMET03219 | ||
| 0.268 | 0.081 | 0.268 | 5 Hydroxytryptamine release stimulant | 0.266 0.082 DBMET03538 0.174 0.148 DBMET03219 | ||
| 0.207 | 0.025 | 0.207 | GABA C receptor rho-2 antagonist | 0.172 0.048 DBMET03538 0.206 0.026 DBMET03219 | ||
| 0.184 | 0.008 | 0.184 | Cyclin B3 inhibitor | 0.15 0.013 DBMET03538 0.152 0.013 DBMET03219 | ||
| 0.182 | 0.007 | 0.306 | Biliverdin reductase inhibitor | 0.179 0.007 DBMET03538 0.306 0.003 DBMET03219 | DBMET03219 | |
| 0.226 | 0.051 | 0.226 | Focal adhesion kinase 2 inhibitor | 0.156 0.122 DBMET03538 0.174 0.095 DBMET03219 | ||
| 0.213 | 0.046 | 0.213 | Tumour necrosis factor antagonist | 0.18 0.067 DBMET03538 0.142 0.111 DBMET03219 | ||
| 0.225 | 0.062 | 0.225 | Anesthetic general | 0.173 0.092 DBMET03538 0.173 0.092 DBMET03219 | ||
| 0.261 | 0.098 | 0.261 | Nootropic | 0.219 0.135 DBMET03538 | ||
| 0.238 | 0.08 | 0.238 | Tyrosine 3 hydroxylase inhibitor | 0.224 0.097 DBMET03538 0.236 0.083 DBMET03219 | ||
| 0.175 | 0.02 | 0.329 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.286 0.007 DBMET03538 0.329 0.005 DBMET03219 | DBMET03219 | |
| 0.191 | 0.036 | 0.206 | Hemostatic | 0.202 0.032 DBMET03538 0.206 0.03 DBMET03219 | DBMET03219 | |
| 0.165 | 0.015 | 0.165 | Potassium channel activator | 0.096 0.053 DBMET03538 0.13 0.028 DBMET03219 | ||
| 0.267 | 0.118 | 0.345 | Vasodilator, coronary | 0.306 0.083 DBMET03538 0.345 0.057 DBMET03219 | DBMET03219 | |
| 0.2 | 0.051 | 0.259 | 3C-like protease (Human coronavirus) inhibitor | 0.176 0.068 DBMET03538 0.259 0.024 DBMET03219 | DBMET03219 | |
| 0.198 | 0.05 | 0.293 | Succinate dehydrogenase inhibitor | 0.207 0.043 DBMET03538 0.293 0.012 DBMET03219 | DBMET03219 | |
| 0.18 | 0.033 | 0.259 | Aldehyde dehydrogenase inhibitor | 0.243 0.019 DBMET03538 0.259 0.017 DBMET03219 | DBMET03219 | |
| 0.166 | 0.02 | 0.166 | Gastric antisecretory | 0.113 0.049 DBMET03538 0.097 0.069 DBMET03219 | ||
| 0.239 | 0.093 | 0.269 | 5 Hydroxytryptamine uptake stimulant | 0.227 0.107 DBMET03538 0.269 0.064 DBMET03219 | DBMET03219 | |
| 0.263 | 0.118 | 0.48 | Vasodilator, peripheral | 0.48 0.032 DBMET03538 0.451 0.04 DBMET03219 | DBMET03538 | |
| 0.233 | 0.089 | 0.415 | Aldehyde oxidase inhibitor | 0.2 0.104 DBMET03538 0.415 0.045 DBMET03219 | DBMET03219 | |
| 0.183 | 0.039 | 0.43 | Alpha-N-acetylglucosaminidase inhibitor | 0.331 0.013 DBMET03538 0.43 0.008 DBMET03219 | DBMET03219 | |
| 0.15 | 0.006 | 0.162 | Glutamate (mGluR1) antagonist | 0.072 0.028 DBMET03538 0.162 0.005 DBMET03219 | DBMET03219 | |
| 0.162 | 0.02 | 0.173 | Ca2+-transporting ATPase inhibitor | 0.154 0.034 DBMET03538 0.173 0.011 DBMET03219 | DBMET03219 | |
| 0.182 | 0.041 | 0.196 | Mannose-6-phosphate isomerase inhibitor | 0.196 0.033 DBMET03538 0.188 0.037 DBMET03219 | DBMET03538 | |
| 0.262 | 0.121 | 0.262 | Prostaglandin dehydrogenase inhibitor | 0.182 0.17 DBMET03219 | ||
| 0.301 | 0.161 | 0.301 | DNA directed DNA polymerase inhibitor | 0.249 0.192 DBMET03219 | ||
| 0.197 | 0.059 | 0.197 | Amyloid beta precursor protein antagonist | 0.191 0.063 DBMET03219 | ||
| 0.181 | 0.048 | 0.227 | Hexokinase inhibitor | 0.198 0.036 DBMET03538 0.227 0.023 DBMET03219 | DBMET03219 | |
| 0.223 | 0.091 | 0.276 | Tumour necrosis factor alpha release inhibitor | 0.276 0.063 DBMET03538 | DBMET03538 | |
| 0.145 | 0.015 | 0.145 | Macrophage colony-stimulating factor 1 receptor antagonist | 0.118 0.023 DBMET03538 | ||
| 0.223 | 0.095 | 0.344 | Superoxide dismutase inhibitor | 0.2 0.117 DBMET03538 0.344 0.038 DBMET03219 | DBMET03219 | |
| 0.136 | 0.011 | 0.136 | Benzodiazepine agonist | 0.097 0.027 DBMET03538 0.075 0.044 DBMET03219 | ||
| 0.154 | 0.03 | 0.282 | Bronchodilator | 0.282 0.01 DBMET03538 0.137 0.036 DBMET03219 | DBMET03538 | |
| 0.155 | 0.033 | 0.177 | GABA receptor agonist | 0.177 0.024 DBMET03538 0.1 0.076 DBMET03219 | DBMET03538 | |
| 0.147 | 0.026 | 0.147 | Transcription factor STAT6 inhibitor | 0.107 0.087 DBMET03538 0.111 0.078 DBMET03219 | ||
| 0.135 | 0.015 | 0.135 | Bromodomain-containing protein 2 inhibitor | 0.081 0.074 DBMET03538 0.086 0.063 DBMET03219 | ||
| 0.249 | 0.128 | 0.251 | Transcription factor NF kappa B inhibitor | 0.251 0.127 DBMET03538 0.239 0.135 DBMET03219 | DBMET03538 | |
| 0.207 | 0.088 | 0.207 | Potassium channel blocker | |||
| 0.14 | 0.023 | 0.277 | Triose-phosphate isomerase inhibitor | 0.21 0.01 DBMET03538 0.277 0.005 DBMET03219 | DBMET03219 | |
| 0.17 | 0.055 | 0.17 | Heat shock protein 90 antagonist | 0.119 0.115 DBMET03538 0.148 0.077 DBMET03219 | ||
| 0.141 | 0.028 | 0.207 | Creatine kinase inhibitor | 0.13 0.034 DBMET03538 0.207 0.009 DBMET03219 | DBMET03219 | |
| 0.138 | 0.025 | 0.138 | Acetylcholine release stimulant | 0.124 0.042 DBMET03538 0.113 0.06 DBMET03219 | ||
| 0.135 | 0.022 | 0.135 | Acetylcholine nicotinic agonist | 0.099 0.038 DBMET03538 0.096 0.04 DBMET03219 | ||
| 0.209 | 0.098 | 0.209 | MAP kinase kinase 3 inhibitor | |||
| 0.154 | 0.044 | 0.277 | TRKB antagonist | 0.277 0.013 DBMET03538 | DBMET03538 | |
| 0.143 | 0.039 | 0.143 | 5 Hydroxytryptamine 3A agonist | |||
| 0.154 | 0.052 | 0.16 | NADPH oxidase inhibitor | 0.128 0.073 DBMET03538 0.16 0.048 DBMET03219 | DBMET03219 | |
| 0.132 | 0.032 | 0.132 | Hedgehog signaling inhibitor | |||
| 0.125 | 0.026 | 0.204 | NADH dehydrogenase inhibitor | 0.172 0.013 DBMET03538 0.204 0.01 DBMET03219 | DBMET03219 | |
| 0.142 | 0.044 | 0.211 | Cystathionine beta-synthase inhibitor | 0.12 0.058 DBMET03538 0.211 0.022 DBMET03219 | DBMET03219 | |
| 0.123 | 0.026 | 0.123 | CYP2A6 inhibitor | |||
| 0.154 | 0.06 | 0.154 | Toll-Like receptor 9 antagonist | |||
| 0.118 | 0.025 | 0.127 | GABA A receptor agonist | 0.127 0.021 DBMET03538 | DBMET03538 | |
| 0.112 | 0.019 | 0.112 | Caspase 7 inhibitor | 0.079 0.064 DBMET03538 0.081 0.058 DBMET03219 | ||
| 0.104 | 0.011 | 0.223 | AMPA receptor antagonist | 0.119 0.009 DBMET03538 0.223 0.004 DBMET03219 | DBMET03219 | |
| 0.101 | 0.009 | 0.101 | Exportin-1 inhibitor | 0.075 0.033 DBMET03538 0.076 0.031 DBMET03219 | ||
| 0.154 | 0.064 | 0.154 | Activin receptor-like kinase 2 inhibitor | 0.13 0.085 DBMET03538 | ||
| 0.187 | 0.098 | 0.187 | HERG channel blocker | |||
| 0.123 | 0.034 | 0.123 | Hepatocyte growth factor antagonist | 0.092 0.06 DBMET03538 | ||
| 0.122 | 0.033 | 0.23 | Alcohol dehydrogenase inhibitor | 0.116 0.038 DBMET03538 0.23 0.009 DBMET03219 | DBMET03219 | |
| 0.096 | 0.009 | 0.096 | Cyclin D1 inhibitor | 0.092 0.01 DBMET03538 0.073 0.025 DBMET03219 | ||
| 0.145 | 0.058 | 0.145 | Sodium channel (voltage-gated) blocker | 0.122 0.082 DBMET03538 | ||
| 0.125 | 0.039 | 0.228 | Adenylate kinase inhibitor | 0.157 0.024 DBMET03538 0.228 0.012 DBMET03219 | DBMET03219 | |
| 0.09 | 0.005 | 0.09 | Melatonin antagonist | 0.043 0.009 DBMET03538 0.03 0.018 DBMET03219 | ||
| 0.1 | 0.014 | 0.165 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.165 0.008 DBMET03538 0.095 0.015 DBMET03219 | DBMET03538 | |
| 0.267 | 0.182 | 0.267 | DNA polymerase beta inhibitor | |||
| 0.153 | 0.07 | 0.16 | CF transmembrane conductance regulator agonist | 0.16 0.059 DBMET03538 | DBMET03538 | |
| 0.094 | 0.011 | 0.094 | Glutamate (mGluR5) antagonist | |||
| 0.098 | 0.016 | 0.098 | Phospholipase D inhibitor | 0.086 0.026 DBMET03538 0.096 0.017 DBMET03219 | ||
| 0.091 | 0.009 | 0.143 | Nicotinic acid receptor 1 agonist | 0.051 0.02 DBMET03538 0.143 0.005 DBMET03219 | DBMET03219 | |
| 0.225 | 0.144 | 0.473 | Cholesterol antagonist | 0.446 0.041 DBMET03538 0.473 0.037 DBMET03219 | DBMET03219 | |
| 0.137 | 0.057 | 0.138 | Cathepsin H inhibitor | 0.109 0.091 DBMET03538 0.138 0.055 DBMET03219 | DBMET03219 | |
| 0.177 | 0.098 | 0.177 | MAP kinase kinase 2 inhibitor | 0.161 0.112 DBMET03538 0.148 0.123 DBMET03219 | ||
| 0.119 | 0.04 | 0.181 | GABA C receptor rho-1 antagonist | 0.106 0.054 DBMET03538 0.181 0.012 DBMET03219 | DBMET03219 | |
| 0.093 | 0.015 | 0.097 | Glutamate (mGluR7) antagonist | 0.071 0.041 DBMET03538 0.097 0.012 DBMET03219 | DBMET03219 | |
| 0.135 | 0.058 | 0.142 | TRKA antagonist | 0.142 0.054 DBMET03538 | DBMET03538 | |
| 0.143 | 0.066 | 0.159 | Heat shock protein 70 antagonist | 0.136 0.093 DBMET03538 0.159 0.03 DBMET03219 | DBMET03219 | |
| 0.086 | 0.009 | 0.086 | Glutamate (mGluR5) agonist | 0.063 0.016 DBMET03538 0.041 0.04 DBMET03219 | ||
| 0.177 | 0.102 | 0.222 | Neurotrophic factor enhancer | 0.222 0.057 DBMET03538 | DBMET03538 | |
| 0.12 | 0.047 | 0.174 | Mediator release inhibitor | 0.121 0.047 DBMET03538 0.174 0.02 DBMET03219 | DBMET03219 | |
| 0.091 | 0.02 | 0.091 | Orexin receptor 1 antagonist | |||
| 0.094 | 0.023 | 0.094 | Acetylcholine M5 receptor agonist | |||
| 0.129 | 0.058 | 0.13 | Sphingosine 1-phosphate receptor 4 antagonist | 0.13 0.055 DBMET03538 0.126 0.063 DBMET03219 | DBMET03538 | |
| 0.109 | 0.038 | 0.109 | Histamine N-methyltransferase inhibitor | 0.109 0.039 DBMET03219 | ||
| 0.12 | 0.05 | 0.371 | GABA C receptor agonist | 0.142 0.037 DBMET03538 0.371 0.006 DBMET03219 | DBMET03219 | |
| 0.203 | 0.134 | 0.203 | Transcription factor STAT inhibitor | 0.191 0.151 DBMET03538 | ||
| 0.078 | 0.009 | 0.078 | Glutamate (mGluR1a) antagonist | 0.049 0.022 DBMET03219 | ||
| 0.101 | 0.032 | 0.104 | mTOR complex 2 inhibitor | 0.104 0.029 DBMET03538 0.081 0.065 DBMET03219 | DBMET03538 | |
| 0.084 | 0.016 | 0.084 | Nicotinic alpha7 receptor agonist | |||
| 0.083 | 0.015 | 0.083 | Corticotropin releasing factor 2 receptor antagonist | |||
| 0.138 | 0.07 | 0.138 | Nav1.6 sodium channel blocker | |||
| 0.085 | 0.018 | 0.085 | Nicotinic neuronal receptor agonist | |||
| 0.203 | 0.137 | 0.203 | Lipoxygenase inhibitor | 0.198 0.142 DBMET03538 0.177 0.167 DBMET03219 | ||
| 0.069 | 0.004 | 0.069 | Melatonin 1 antagonist | 0.027 0.007 DBMET03538 0.02 0.012 DBMET03219 | ||
| 0.087 | 0.023 | 0.198 | DNA gyrase inhibitor | 0.075 0.031 DBMET03538 0.198 0.005 DBMET03219 | DBMET03219 | |
| 0.078 | 0.013 | 0.078 | Glutamate (mGluR group I) agonist | 0.068 0.017 DBMET03538 0.043 0.039 DBMET03219 | ||
| 0.096 | 0.033 | 0.209 | Glutamate dehydrogenase inhibitor | 0.12 0.023 DBMET03538 0.209 0.009 DBMET03219 | DBMET03219 | |
| 0.077 | 0.014 | 0.077 | Purinergic P2X antagonist | |||
| 0.17 | 0.108 | 0.209 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.209 0.065 DBMET03538 0.203 0.07 DBMET03219 | DBMET03538 | |
| 0.083 | 0.023 | 0.373 | Alcohol oxidase inhibitor | 0.104 0.017 DBMET03538 0.373 0.004 DBMET03219 | DBMET03219 | |
| 0.195 | 0.137 | 0.195 | 5 Hydroxytryptamine 1E antagonist | |||
| 0.091 | 0.034 | 0.091 | CC chemokine 5 receptor agonist | |||
| 0.174 | 0.118 | 0.174 | Aryl hydrocarbon receptor agonist | |||
| 0.127 | 0.071 | 0.136 | Antibacterial (Helicobacter pylori) | 0.11 0.098 DBMET03538 0.136 0.06 DBMET03219 | DBMET03219 | |
| 0.114 | 0.059 | 0.157 | GABA C receptor antagonist | 0.102 0.075 DBMET03538 0.157 0.026 DBMET03219 | DBMET03219 | |
| 0.173 | 0.118 | 0.173 | Potassium channel (Voltage-sensitive) blocker | |||
| 0.081 | 0.026 | 0.081 | Orexin receptor antagonist | |||
| 0.105 | 0.05 | 0.105 | Glutamate (mGluR7) agonist | 0.091 0.081 DBMET03538 0.089 0.086 DBMET03219 | ||
| 0.142 | 0.087 | 0.196 | Anticoagulant | 0.134 0.095 DBMET03538 0.196 0.054 DBMET03219 | DBMET03219 | |
| 0.063 | 0.008 | 0.079 | Nerve growth factor antagonist | 0.079 0.004 DBMET03219 | DBMET03219 | |
| 0.136 | 0.084 | 0.136 | Pregnane X receptor agonist | |||
| 0.104 | 0.052 | 0.104 | Interleukin 1 beta converting enzyme inhibitor | 0.087 0.077 DBMET03538 0.089 0.073 DBMET03219 | ||
| 0.145 | 0.094 | 0.156 | Arachidonic acid antagonist | 0.128 0.116 DBMET03538 0.156 0.082 DBMET03219 | DBMET03219 | |
| 0.115 | 0.064 | 0.118 | Photosensitizer | 0.118 0.059 DBMET03538 0.115 0.063 DBMET03219 | DBMET03538 | |
| 0.14 | 0.09 | 0.14 | Cyclin-dependent kinase 8 inhibitor | |||
| 0.064 | 0.016 | 0.064 | Potassium channel (Inward rectifier) activator | |||
| 0.125 | 0.077 | 0.141 | Toll-Like receptor antagonist | 0.141 0.062 DBMET03538 | DBMET03538 | |
| 0.102 | 0.055 | 0.202 | Electrolyte absorption antagonist | 0.202 0.008 DBMET03219 | DBMET03219 | |
| 0.06 | 0.013 | 0.06 | Benzodiazepine antagonist | |||
| 0.088 | 0.042 | 0.088 | Nicotinic alpha4beta2 receptor antagonist | |||
| 0.057 | 0.011 | 0.064 | Vascular adhesion protein 1 inhibitor | 0.064 0.008 DBMET03538 | DBMET03538 | |
| 0.057 | 0.011 | 0.072 | DNA gyrase subunit A inhibitor | 0.06 0.01 DBMET03538 0.072 0.006 DBMET03219 | DBMET03219 | |
| 0.066 | 0.02 | 0.066 | H+/K+-transporting ATPase inhibitor | |||
| 0.061 | 0.015 | 0.061 | Potassium channel (ATP-sensitive) activator | |||
| 0.063 | 0.018 | 0.063 | Immunoglobulin Fc receptor antagonist | 0.053 0.048 DBMET03538 0.054 0.043 DBMET03219 | ||
| 0.099 | 0.054 | 0.099 | Phosphodiesterase 6D inhibitor | 0.088 0.08 DBMET03538 | ||
| 0.062 | 0.018 | 0.062 | Factor X inhibitor | 0.034 0.031 DBMET03219 | ||
| 0.126 | 0.081 | 0.127 | Tyrosine-protein kinase receptor antagonist | 0.127 0.08 DBMET03538 | DBMET03538 | |
| 0.052 | 0.008 | 0.069 | Uridine phosphorylase inhibitor | 0.069 0.004 DBMET03538 0.063 0.005 DBMET03219 | DBMET03538 | |
| 0.094 | 0.051 | 0.094 | Androgen antagonist | 0.076 0.07 DBMET03538 | ||
| 0.062 | 0.018 | 0.062 | Smo receptor antagonist | |||
| 0.199 | 0.155 | 0.199 | Thyroid hormone beta antagonist | |||
| 0.068 | 0.025 | 0.07 | Toll-Like receptor 8 antagonist | 0.07 0.023 DBMET03538 | DBMET03538 | |
| 0.097 | 0.055 | 0.097 | Alpha 2d adrenoreceptor antagonist | |||
| 0.052 | 0.011 | 0.052 | MAP3K5 inhibitor | 0.048 0.015 DBMET03538 | ||
| 0.077 | 0.036 | 0.077 | Nav1.7 sodium channel blocker | 0.061 0.056 DBMET03538 | ||
| 0.098 | 0.057 | 0.121 | Prolactin inhibitor | 0.121 0.038 DBMET03538 0.081 0.079 DBMET03219 | DBMET03538 | |
| 0.066 | 0.026 | 0.066 | Melanin-concentrating hormone receptor 1 antagonist | 0.06 0.03 DBMET03538 | ||
| 0.128 | 0.088 | 0.187 | Cell wall synthesis inhibitor | 0.129 0.087 DBMET03538 0.187 0.036 DBMET03219 | DBMET03219 | |
| 0.198 | 0.159 | 0.198 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.195 0.164 DBMET03538 | ||
| 0.05 | 0.011 | 0.05 | Purinergic P2X3 antagonist | |||
| 0.046 | 0.007 | 0.046 | Nicotinic alpha3beta4 receptor agonist | |||
| 0.092 | 0.053 | 0.092 | Acetylcholine agonist | |||
| 0.2 | 0.162 | 0.2 | Thyroid hormone antagonist | |||
| 0.069 | 0.032 | 0.069 | Transcription factor RelA inhibitor | |||
| 0.057 | 0.02 | 0.057 | Cholesterol esterase inhibitor | |||
| 0.107 | 0.071 | 0.107 | Activin receptor-like kinase 4 inhibitor | |||
| 0.046 | 0.011 | 0.05 | Free fatty acid receptor 1 antagonist | 0.044 0.012 DBMET03538 0.05 0.009 DBMET03219 | DBMET03219 | |
| 0.069 | 0.033 | 0.069 | Cyclin B1 inhibitor | 0.057 0.047 DBMET03538 | ||
| 0.204 | 0.169 | 0.204 | Thioredoxin glutathione reductase inhibitor | |||
| 0.116 | 0.081 | 0.151 | DNA repair enzyme inhibitor | 0.151 0.03 DBMET03538 0.116 0.08 DBMET03219 | DBMET03538 | |
| 0.101 | 0.066 | 0.103 | Urease inhibitor | 0.103 0.064 DBMET03219 | DBMET03219 | |
| 0.072 | 0.038 | 0.072 | Purinergic P2 antagonist | |||
| 0.066 | 0.032 | 0.066 | Enoyl-[acyl-carrier-protein] reductase inhibitor | |||
| 0.062 | 0.029 | 0.062 | Cyclin B2 inhibitor | 0.055 0.04 DBMET03538 | ||
| 0.077 | 0.044 | 0.077 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.07 0.061 DBMET03219 | ||
| 0.073 | 0.041 | 0.079 | Protein kinase C beta inhibitor | 0.075 0.038 DBMET03538 0.079 0.031 DBMET03219 | DBMET03219 | |
| 0.076 | 0.044 | 0.098 | Glycine receptor agonist | 0.098 0.022 DBMET03219 | DBMET03219 | |
| 0.078 | 0.045 | 0.078 | Phosphodiesterase VI inhibitor | |||
| 0.046 | 0.015 | 0.122 | Glutamate (mGluR3) antagonist | 0.058 0.009 DBMET03538 0.122 0.004 DBMET03219 | DBMET03219 | |
| 0.04 | 0.009 | 0.057 | DNA topoisomerase IV inhibitor | 0.036 0.012 DBMET03538 0.057 0.005 DBMET03219 | DBMET03219 | |
| 0.13 | 0.098 | 0.328 | NOS3 expression enhancer | 0.127 0.103 DBMET03538 0.328 0.014 DBMET03219 | DBMET03219 | |
| 0.15 | 0.119 | 0.209 | I kappa B kinase epsilon inhibitor | 0.162 0.107 DBMET03538 0.209 0.063 DBMET03219 | DBMET03219 | |
| 0.084 | 0.054 | 0.084 | Estrogen-related receptor beta agonist | |||
| 0.087 | 0.057 | 0.103 | Granulocyte macrophage colony stimulating factor agonist | 0.103 0.031 DBMET03538 0.093 0.045 DBMET03219 | DBMET03538 | |
| 0.06 | 0.03 | 0.06 | GABA A receptor antagonist | |||
| 0.065 | 0.036 | 0.065 | Phosphodiesterase 1C inhibitor | 0.062 0.043 DBMET03538 | ||
| 0.081 | 0.052 | 0.099 | Glutamate receptor agonist | 0.097 0.04 DBMET03538 0.099 0.038 DBMET03219 | DBMET03219 | |
| 0.061 | 0.033 | 0.132 | Acyl-CoA dehydrogenase inhibitor | 0.08 0.022 DBMET03538 0.132 0.011 DBMET03219 | DBMET03219 | |
| 0.206 | 0.179 | 0.206 | Ca(v)3.3 blocker | |||
| 0.116 | 0.089 | 0.116 | Sodium channel blocker | |||
| 0.062 | 0.035 | 0.145 | Argininosuccinate synthase inhibitor | 0.079 0.026 DBMET03538 0.145 0.012 DBMET03219 | DBMET03219 | |
| 0.084 | 0.057 | 0.102 | D-Ala-D-Ala ligase inhibitor | 0.078 0.074 DBMET03538 0.102 0.027 DBMET03219 | DBMET03219 | |
| 0.036 | 0.01 | 0.036 | Nicotinic alpha4beta2 receptor agonist | |||
| 0.058 | 0.032 | 0.072 | Dihydroorotate oxidase inhibitor | 0.072 0.015 DBMET03219 | DBMET03219 | |
| 0.065 | 0.039 | 0.1 | Carbamoyl phosphate synthetase inhibitor | 0.1 0.02 DBMET03538 0.086 0.026 DBMET03219 | DBMET03538 | |
| 0.076 | 0.051 | 0.098 | GABA B receptor agonist | 0.074 0.056 DBMET03538 0.098 0.018 DBMET03219 | DBMET03219 | |
| 0.043 | 0.018 | 0.043 | Orexin receptor 2 antagonist | |||
| 0.198 | 0.172 | 0.198 | Ca2+/calmodulin-dependent kinase IV inhibitor | |||
| 0.067 | 0.042 | 0.067 | Aryl hydrocarbon receptor antagonist | |||
| 0.104 | 0.08 | 0.104 | TRPA1 agonist | 0.099 0.09 DBMET03219 | ||
| 0.058 | 0.034 | 0.058 | GABA receptor antagonist | |||
| 0.13 | 0.106 | 0.141 | MAP kinase 3 inhibitor | 0.141 0.083 DBMET03538 | DBMET03538 | |
| 0.055 | 0.031 | 0.153 | Aconitate hydratase inhibitor | 0.066 0.021 DBMET03538 0.153 0.004 DBMET03219 | DBMET03219 | |
| 0.225 | 0.202 | 0.225 | Alpha-glucosidase inhibitor | |||
| 0.069 | 0.046 | 0.069 | Sphingosine 1-phosphate receptor 4 agonist | |||
| 0.046 | 0.023 | 0.046 | Cyclin D3 inhibitor | |||
| 0.044 | 0.021 | 0.044 | G protein-coupled receptor agonist | 0.036 0.028 DBMET03538 | ||
| 0.06 | 0.038 | 0.06 | Cyclin A1 inhibitor | |||
| 0.04 | 0.018 | 0.04 | Glucose-dependent insulinotropic receptor agonist | |||
| 0.097 | 0.075 | 0.097 | Granulocyte macrophage colony stimulating factor antagonist | |||
| 0.041 | 0.02 | 0.173 | Nicotinic acid receptor agonist | 0.043 0.019 DBMET03538 0.173 0.004 DBMET03219 | DBMET03219 | |
| 0.044 | 0.024 | 0.052 | Thymidine kinase inhibitor | 0.052 0.017 DBMET03538 | DBMET03538 | |
| 0.078 | 0.059 | 0.078 | Glycine receptor antagonist | 0.074 0.067 DBMET03219 | ||
| 0.068 | 0.049 | 0.141 | Phenylalanine 4-hydroxylase inhibitor | 0.08 0.037 DBMET03538 0.141 0.013 DBMET03219 | DBMET03219 | |
| 0.058 | 0.039 | 0.188 | Xanthine dehydrogenase inhibitor | 0.092 0.018 DBMET03538 0.188 0.005 DBMET03219 | DBMET03219 | |
| 0.037 | 0.018 | 0.037 | CDK6/cyclin D3 inhibitor | |||
| 0.022 | 0.003 | 0.022 | Cyclin D2 inhibitor | 0.016 0.005 DBMET03538 0.014 0.008 DBMET03219 | ||
| 0.044 | 0.026 | 0.044 | CDK5/p25 inhibitor | |||
| 0.066 | 0.049 | 0.089 | MDM2 inhibitor | 0.073 0.03 DBMET03538 0.089 0.012 DBMET03219 | DBMET03219 | |
| 0.053 | 0.036 | 0.053 | Nicotinic alpha3beta2 receptor antagonist | |||
| 0.107 | 0.09 | 0.226 | Amylase inhibitor | 0.226 0.035 DBMET03538 0.124 0.078 DBMET03219 | DBMET03538 | |
| 0.059 | 0.042 | 0.059 | Androgen agonist | 0.055 0.048 DBMET03538 | ||
| 0.039 | 0.023 | 0.039 | Vanilloid 3 antagonist | |||
| 0.09 | 0.074 | 0.145 | Carbonic anhydrase III inhibitor | 0.13 0.038 DBMET03538 0.145 0.03 DBMET03219 | DBMET03219 | |
| 0.089 | 0.073 | 0.16 | Aminopeptidase B inhibitor | 0.098 0.066 DBMET03538 0.16 0.034 DBMET03219 | DBMET03219 | |
| 0.129 | 0.114 | 0.155 | Interferon gamma antagonist | 0.132 0.106 DBMET03538 0.155 0.071 DBMET03219 | DBMET03219 | |
| 0.056 | 0.041 | 0.056 | Fatty acid synthase inhibitor | |||
| 0.13 | 0.115 | 0.135 | Melanin inhibitor | 0.135 0.106 DBMET03538 | DBMET03538 | |
| 0.028 | 0.014 | 0.03 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.03 0.011 DBMET03538 | DBMET03538 | |
| 0.049 | 0.035 | 0.049 | Phosphatidylinositol 3-kinase beta inhibitor | |||
| 0.165 | 0.151 | 0.285 | DNA damaging | 0.285 0.064 DBMET03538 0.163 0.154 DBMET03219 | DBMET03538 | |
| 0.029 | 0.015 | 0.029 | Glucosylceramidase stimulant | |||
| 0.039 | 0.025 | 0.084 | DNA gyrase subunit B inhibitor | 0.035 0.031 DBMET03538 0.084 0.005 DBMET03219 | DBMET03219 | |
| 0.101 | 0.088 | 0.101 | Beta amyloid protein antagonist | |||
| 0.167 | 0.154 | 0.167 | MAP-kinase-activated kinase 5 inhibitor | |||
| 0.027 | 0.015 | 0.027 | Acid ceramidase inhibitor | |||
| 0.063 | 0.051 | 0.063 | Neuronal nicotinic receptor antagonist | |||
| 0.018 | 0.007 | 0.047 | Egl nine homolog 1 inhibitor | 0.017 0.008 DBMET03538 0.047 0.003 DBMET03219 | DBMET03219 | |
| 0.053 | 0.041 | 0.053 | Cyclin B inhibitor | |||
| 0.095 | 0.084 | 0.095 | Glycogen synthase kinase-3 beta inhibitor | |||
| 0.125 | 0.113 | 0.141 | Adenylate cyclase stimulant | 0.141 0.079 DBMET03538 0.128 0.106 DBMET03219 | DBMET03538 | |
| 0.068 | 0.057 | 0.068 | MAP kinase 14 inhibitor | |||
| 0.043 | 0.032 | 0.124 | Glutamate (mGluR group III) antagonist | 0.124 0.004 DBMET03219 | DBMET03219 | |
| 0.042 | 0.032 | 0.135 | Glutamate (mGluR4) antagonist | 0.042 0.034 DBMET03538 0.135 0.004 DBMET03219 | DBMET03219 | |
| 0.057 | 0.048 | 0.057 | Phosphodiesterase 1A inhibitor | |||
| 0.044 | 0.035 | 0.044 | Parathyroid hormone antagonist | |||
| 0.062 | 0.053 | 0.062 | 5 Hydroxytryptamine 3A antagonist | |||
| 0.014 | 0.006 | 0.027 | Egl nine homolog 3 inhibitor | 0.027 0.004 DBMET03219 | DBMET03219 | |
| 0.037 | 0.029 | 0.051 | Glutamate (mGluR group II) antagonist | 0.051 0.015 DBMET03538 0.05 0.016 DBMET03219 | DBMET03538 | |
| 0.07 | 0.063 | 0.07 | Potassium channel (Tandem pore domain) blocker | |||
| 0.066 | 0.059 | 0.102 | Aminopeptidase I inhibitor | 0.065 0.061 DBMET03538 0.102 0.027 DBMET03219 | DBMET03219 | |
| 0.054 | 0.047 | 0.054 | CDK4/cyclin D inhibitor | |||
| 0.04 | 0.033 | 0.055 | Guanylate cyclase inhibitor | 0.055 0.016 DBMET03538 0.05 0.021 DBMET03219 | DBMET03538 | |
| 0.021 | 0.014 | 0.021 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.021 0.014 DBMET03538 | ||
| 0.123 | 0.117 | 0.154 | Sphingosine 1-phosphate receptor 5 antagonist | 0.154 0.055 DBMET03219 | DBMET03219 | |
| 0.027 | 0.022 | 0.027 | Estrogen-related receptor gamma antagonist | 0.027 0.025 DBMET03538 | ||
| 0.043 | 0.038 | 0.049 | Thymidylate synthase inhibitor | 0.049 0.029 DBMET03538 0.044 0.036 DBMET03219 | DBMET03538 | |
| 0.061 | 0.056 | 0.061 | Calcium channel P-type blocker | |||
| 0.033 | 0.029 | 0.033 | AMPA receptor agonist | |||
| 0.025 | 0.021 | 0.031 | Thymidine phosphorylase inhibitor | 0.031 0.011 DBMET03538 | DBMET03538 | |
| 0.017 | 0.013 | 0.017 | CC chemokine 9 receptor antagonist | |||
| 0.049 | 0.046 | 0.075 | Carbonic anhydrase VB inhibitor | 0.075 0.025 DBMET03538 0.064 0.032 DBMET03219 | DBMET03538 | |
| 0.055 | 0.052 | 0.055 | 5 Hydroxytryptamine 2A agonist | |||
| 0.039 | 0.035 | 0.055 | Angiotensin AT1 receptor antagonist | 0.055 0.011 DBMET03219 | DBMET03219 | |
| 0.042 | 0.039 | 0.042 | Purinergic P2X4 antagonist | |||
| 0.085 | 0.082 | 0.088 | Lanosterol 14 alpha demethylase inhibitor | 0.088 0.076 DBMET03538 | DBMET03538 | |
| 0.026 | 0.023 | 0.026 | Cyclin E2 inhibitor | |||
| 0.138 | 0.136 | 0.138 | Death-associated protein kinase 2 inhibitor | |||
| 0.053 | 0.051 | 0.062 | Pregnane X receptor antagonist | 0.062 0.027 DBMET03219 | DBMET03219 | |
| 0.015 | 0.013 | 0.015 | Nicotinic alpha4 receptor agonist | |||
| 0.069 | 0.067 | 0.07 | Vanilloid 4 agonist | 0.07 0.063 DBMET03538 | DBMET03538 | |
| 0.018 | 0.016 | 0.018 | Guanylate cyclase 1 stimulant | |||
| 0.097 | 0.096 | 0.097 | Microtubule formation inhibitor | |||
| 0.093 | 0.093 | 0.202 | Topoisomerase II inhibitor | 0.168 0.042 DBMET03538 0.202 0.033 DBMET03219 | DBMET03219 | |
| 0.061 | 0.061 | 0.205 | Histidine decarboxylase inhibitor | 0.19 0.014 DBMET03538 0.205 0.012 DBMET03219 | DBMET03219 | |
| 0.044 | 0.044 | 0.066 | Topoisomerase II beta inhibitor | 0.065 0.019 DBMET03538 0.066 0.018 DBMET03219 | DBMET03219 | |
| 0.037 | 0.038 | 0.042 | CF transmembrane conductance regulator antagonist | 0.042 0.02 DBMET03538 0.042 0.021 DBMET03219 | DBMET03219 | |
| 0.092 | 0.093 | 0.149 | Protein kinase C gamma inhibitor | 0.121 0.052 DBMET03538 0.149 0.032 DBMET03219 | DBMET03219 | |
| 0.029 | 0.031 | 0.07 | Fumarate hydratase inhibitor | 0.04 0.019 DBMET03538 0.07 0.008 DBMET03219 | DBMET03219 | |
| 0.039 | 0.042 | 0.044 | Guanylate cyclase stimulant | 0.044 0.03 DBMET03219 | DBMET03219 | |
| 0.037 | 0.042 | 0.052 | Oleamide hydrolase inhibitor | 0.052 0.025 DBMET03219 | DBMET03219 | |
| 0.052 | 0.058 | 0.092 | Purinergic P2X1 antagonist | 0.057 0.048 DBMET03538 0.092 0.019 DBMET03219 | DBMET03219 | |
| 0.065 | 0.071 | 0.115 | GABA aminotransferase inhibitor | 0.115 0.018 DBMET03219 | DBMET03219 | |
| 0.061 | 0.067 | 0.152 | Glutamate decarboxylase inhibitor | 0.071 0.054 DBMET03538 0.152 0.013 DBMET03219 | DBMET03219 | |
| 0.077 | 0.083 | 0.09 | Phosphodiesterase I inhibitor | 0.09 0.059 DBMET03538 | DBMET03538 | |
| 0.112 | 0.118 | 0.115 | Sphingosine 1-phosphate receptor 2 antagonist | 0.115 0.109 DBMET03219 | DBMET03219 | |
| 0.037 | 0.044 | 0.058 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.058 0.008 DBMET03219 | DBMET03219 | |
| 0.066 | 0.075 | 0.156 | Keratolytic | 0.083 0.045 DBMET03538 0.156 0.013 DBMET03219 | DBMET03219 | |
| 0.062 | 0.072 | 0.098 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.098 0.039 DBMET03538 0.078 0.053 DBMET03219 | DBMET03538 | |
| 0.016 | 0.026 | 0.02 | Methylmalonyl-CoA mutase inhibitor | 0.02 0.009 DBMET03219 | DBMET03219 | |
| 0.029 | 0.039 | 0.064 | Farnesoid X receptor agonist | 0.064 0.009 DBMET03219 | DBMET03219 | |
| 0.059 | 0.07 | 0.078 | Glutamate (mGluR6) antagonist | 0.078 0.026 DBMET03219 | DBMET03219 | |
| 0.04 | 0.052 | 0.067 | Dihydroorotate dehydrogenase inhibitor | 0.067 0.023 DBMET03219 | DBMET03219 | |
| 0.028 | 0.04 | 0.042 | Angiotensin II receptor antagonist | 0.042 0.012 DBMET03219 | DBMET03219 | |
| 0.035 | 0.049 | 0.049 | Kainate receptor agonist | 0.049 0.015 DBMET03219 | DBMET03219 | |
| 0.073 | 0.087 | 0.085 | Thioredoxin reductase inhibitor | 0.085 0.049 DBMET03538 | DBMET03538 | |
| 0.042 | 0.058 | 0.095 | Bruton tyrosine kinase inhibitor | 0.095 0.016 DBMET03538 | DBMET03538 | |
| 0.055 | 0.071 | 0.157 | Catalase inhibitor | 0.079 0.048 DBMET03538 0.157 0.024 DBMET03219 | DBMET03219 | |
| 0.039 | 0.055 | 0.056 | Glucose-6-phosphate isomerase inhibitor | 0.056 0.022 DBMET03538 0.045 0.039 DBMET03219 | DBMET03538 | |
| 0.016 | 0.034 | 0.026 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.026 0.021 DBMET03538 | DBMET03538 | |
| 0.028 | 0.047 | 0.058 | Urate transporter 1 inhibitor | 0.058 0.015 DBMET03219 | DBMET03219 | |
| 0.045 | 0.064 | 0.062 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.062 0.037 DBMET03219 | DBMET03219 | |
| 0.031 | 0.05 | 0.049 | Glutamate (mGluR8) agonist | 0.035 0.033 DBMET03538 0.049 0.012 DBMET03219 | DBMET03219 | |
| 0.05 | 0.069 | 0.065 | Leukotriene C antagonist | 0.054 0.046 DBMET03538 0.065 0.019 DBMET03219 | DBMET03219 | |
| 0.069 | 0.088 | 0.076 | MAP kinase kinase 7 inhibitor | 0.076 0.059 DBMET03538 0.075 0.064 DBMET03219 | DBMET03538 | |
| 0.052 | 0.075 | 0.069 | Carbonic anhydrase VA inhibitor | 0.069 0.048 DBMET03538 0.064 0.054 DBMET03219 | DBMET03538 | |
| 0.016 | 0.038 | 0.024 | Retinoid X beta receptor antagonist | 0.024 0.008 DBMET03219 | DBMET03219 | |
| 0.055 | 0.078 | 0.067 | Cathepsin G inhibitor | 0.067 0.058 DBMET03538 | DBMET03538 | |
| 0.086 | 0.109 | 0.134 | DOPA decarboxylase inhibitor | 0.134 0.032 DBMET03219 | DBMET03219 | |
| 0.131 | 0.155 | 0.143 | Neurotensin receptor agonist | 0.143 0.119 DBMET03219 | DBMET03219 | |
| 0.076 | 0.101 | 0.088 | Falcipain 3 inhibitor | 0.088 0.084 DBMET03219 | DBMET03219 | |
| 0.047 | 0.073 | 0.116 | Phosphofructokinase-1 inhibitor | 0.098 0.032 DBMET03538 0.116 0.026 DBMET03219 | DBMET03219 | |
| 0.179 | 0.206 | 0.315 | Antithrombotic | 0.299 0.088 DBMET03538 0.315 0.079 DBMET03219 | DBMET03219 | |
| 0.018 | 0.045 | 0.042 | Nicotinic acid receptor 2 antagonist | 0.042 0.005 DBMET03219 | DBMET03219 | |
| 0.027 | 0.054 | 0.036 | DNA-dependent protein kinase inhibitor | 0.036 0.034 DBMET03538 | DBMET03538 | |
| 0.037 | 0.064 | 0.056 | Lysophosphatidic acid 3 receptor antagonist | 0.051 0.034 DBMET03538 0.056 0.027 DBMET03219 | DBMET03219 | |
| 0.013 | 0.041 | 0.029 | Methionyl aminopeptidase 2 inhibitor | 0.029 0.015 DBMET03219 | DBMET03219 | |
| 0.02 | 0.048 | 0.09 | Kainate receptor 2 antagonist | 0.09 0.005 DBMET03219 | DBMET03219 | |
| 0.091 | 0.122 | 0.131 | Toll-Like receptor 2 antagonist | 0.131 0.067 DBMET03538 | DBMET03538 | |
| 0.061 | 0.092 | 0.131 | Phosphodiesterase 3A inhibitor | 0.131 0.019 DBMET03538 | DBMET03538 | |
| 0.077 | 0.109 | 0.096 | Bile acid receptor antagonist | 0.096 0.058 DBMET03219 | DBMET03219 | |
| 0.097 | 0.129 | 0.16 | Protein kinase stimulant | 0.16 0.062 DBMET03538 | DBMET03538 | |
| 0.077 | 0.109 | 0.09 | DNA intercalator | 0.09 0.085 DBMET03538 | DBMET03538 | |
| 0.021 | 0.054 | 0.062 | Retinoid X alpha receptor agonist | 0.062 0.011 DBMET03219 | DBMET03219 | |
| 0.005 | 0.039 | 0.014 | Angiotensin AT1B receptor antagonist | 0.014 0.01 DBMET03219 | DBMET03219 | |
| 0.018 | 0.054 | 0.027 | Integrin alpha2beta1 antagonist | 0.027 0.017 DBMET03219 | DBMET03219 | |
| 0.031 | 0.067 | 0.045 | AICAR transformylase inhibitor | 0.045 0.029 DBMET03219 | DBMET03219 | |
| 0.031 | 0.067 | 0.042 | Leukotriene C4 antagonist | 0.042 0.019 DBMET03219 | DBMET03219 | |
| 0.03 | 0.067 | 0.053 | Dihydroorotase inhibitor | 0.053 0.021 DBMET03219 | DBMET03219 | |
| 0.104 | 0.142 | 0.177 | Insulin secretagoues | 0.177 0.05 DBMET03219 | DBMET03219 | |
| 0.044 | 0.082 | 0.066 | Carbonic anhydrase V inhibitor | 0.066 0.047 DBMET03538 | DBMET03538 | |
| 0.049 | 0.087 | 0.061 | Ryanodine receptor antagonist | 0.061 0.033 DBMET03219 | DBMET03219 | |
| 0.026 | 0.064 | 0.052 | GABA uptake inhibitor | 0.052 0.014 DBMET03219 | DBMET03219 | |
| 0.009 | 0.049 | 0.028 | Nicotinic acid receptor 1 antagonist | 0.028 0.005 DBMET03219 | DBMET03219 | |
| 0.114 | 0.154 | 0.203 | DNA methyltransferase I inhibitor | 0.203 0.067 DBMET03219 | DBMET03219 | |
| 0.017 | 0.058 | 0.028 | Sodium/glucose cotransporter inhibitor | 0.028 0.013 DBMET03538 | DBMET03538 | |
| 0.028 | 0.07 | 0.042 | Stearoyl-CoA desaturase inhibitor | 0.042 0.034 DBMET03538 | DBMET03538 | |
| 0.04 | 0.083 | 0.065 | Thromboxane synthase inhibitor | 0.052 0.044 DBMET03538 0.065 0.022 DBMET03219 | DBMET03219 | |
| 0.056 | 0.099 | 0.117 | Macrophage migration inhibitory factor inhibitor | 0.117 0.027 DBMET03219 | DBMET03219 | |
| 0.056 | 0.1 | 0.083 | Peroxisome proliferator-activated receptor gamma antagonist | 0.083 0.03 DBMET03219 | DBMET03219 | |
| 0.013 | 0.056 | 0.036 | AMPA 3 receptor antagonist | 0.036 0.016 DBMET03219 | DBMET03219 | |
| 0.027 | 0.07 | 0.048 | Antimetabolite | 0.048 0.033 DBMET03538 | DBMET03538 | |
| 0.02 | 0.064 | 0.041 | TRPM8 blocker | 0.041 0.023 DBMET03219 | DBMET03219 | |
| 0.037 | 0.082 | 0.05 | Cytokine production stimulant | 0.05 0.03 DBMET03538 | DBMET03538 | |
| 0.014 | 0.06 | 0.029 | Sodium/glucose cotransporter 2 inhibitor | 0.029 0.014 DBMET03538 | DBMET03538 | |
| 0.015 | 0.063 | 0.06 | Retinoid X receptor agonist | 0.06 0.014 DBMET03219 | DBMET03219 | |
| 0.025 | 0.072 | 0.055 | Adenosine deaminase inhibitor | 0.055 0.025 DBMET03538 0.05 0.03 DBMET03219 | DBMET03538 | |
| 0.025 | 0.073 | 0.034 | Protein kinase C beta I inhibitor | 0.034 0.021 DBMET03219 | DBMET03219 | |
| 0.024 | 0.072 | 0.036 | Integrin alpha2 antagonist | 0.036 0.027 DBMET03219 | DBMET03219 | |
| 0.008 | 0.056 | 0.073 | AMPA 1 receptor antagonist | 0.073 0.008 DBMET03219 | DBMET03219 | |
| 0.073 | 0.122 | 0.09 | Glutamate release inhibitor | 0.09 0.063 DBMET03538 | DBMET03538 | |
| 0.015 | 0.065 | 0.051 | HCV NS5B polymerase inhibitor | 0.051 0.01 DBMET03219 | DBMET03219 | |
| 0.071 | 0.122 | 0.134 | Xanthine oxidase inhibitor | 0.086 0.079 DBMET03538 0.134 0.041 DBMET03219 | DBMET03219 | |
| 0.023 | 0.074 | 0.04 | Retinoid X alpha receptor antagonist | 0.04 0.015 DBMET03219 | DBMET03219 | |
| 0.035 | 0.087 | 0.073 | NMDA receptor glycine site agonist | 0.073 0.034 DBMET03219 | DBMET03219 | |
| 0.015 | 0.067 | 0.041 | Protocollagen prolyl hydroxylase inhibitor | 0.029 0.016 DBMET03538 0.041 0.007 DBMET03219 | DBMET03219 | |
| 0.025 | 0.078 | 0.046 | Retinoid X receptor antagonist | 0.046 0.017 DBMET03219 | DBMET03219 | |
| 0.027 | 0.082 | 0.04 | Glutamate (mGluR group III) agonist | 0.04 0.034 DBMET03219 | DBMET03219 | |
| 0.039 | 0.094 | 0.052 | Glucosylceramidase inhibitor | 0.052 0.044 DBMET03538 | DBMET03538 | |
| 0.031 | 0.086 | 0.06 | Diacylglycerol O-acyltransferase inhibitor | 0.06 0.026 DBMET03219 | DBMET03219 | |
| 0.111 | 0.169 | 0.204 | DNA methylase inhibitor | 0.204 0.077 DBMET03219 | DBMET03219 | |
| 0.025 | 0.084 | 0.062 | Ornithine carbamoyltransferase inhibitor | 0.062 0.03 DBMET03219 | DBMET03219 | |
| 0.072 | 0.133 | 0.123 | Cholesterol synthesis inhibitor | 0.123 0.062 DBMET03219 | DBMET03219 | |
| 0.08 | 0.142 | 0.107 | Cyclooxygenase 3 inhibitor | 0.107 0.094 DBMET03219 | DBMET03219 | |
| 0.071 | 0.134 | 0.104 | Carbonic anhydrase XV inhibitor | 0.099 0.068 DBMET03538 0.104 0.061 DBMET03219 | DBMET03219 | |
| 0.12 | 0.184 | 0.159 | Phospholipase C inhibitor | 0.149 0.107 DBMET03538 0.159 0.089 DBMET03219 | DBMET03219 | |
| 0.004 | 0.073 | 0.043 | Kainate receptor 1 antagonist | 0.043 0.006 DBMET03219 | DBMET03219 | |
| 0.058 | 0.127 | 0.107 | HIV-1 integrase (Overall Integration) inhibitor | 0.107 0.049 DBMET03538 0.1 0.055 DBMET03219 | DBMET03538 | |
| 0.035 | 0.103 | 0.055 | Heparanase inhibitor | 0.055 0.032 DBMET03219 | DBMET03219 | |
| 0.045 | 0.114 | 0.06 | Interferon inducer | 0.06 0.054 DBMET03538 | DBMET03538 | |
| 0.04 | 0.109 | 0.073 | NMDA receptor agonist | 0.073 0.033 DBMET03219 | DBMET03219 | |
| 0.015 | 0.086 | 0.086 | Kainate receptor antagonist | 0.086 0.009 DBMET03219 | DBMET03219 | |
| 0.072 | 0.143 | 0.116 | Glycogen synthase kinase-3 alpha inhibitor | 0.116 0.087 DBMET03219 | DBMET03219 | |
| 0.023 | 0.096 | 0.04 | AMPA 4 receptor antagonist | 0.04 0.027 DBMET03219 | DBMET03219 | |
| 0.051 | 0.127 | 0.076 | Carbonic anhydrase VI inhibitor | 0.076 0.062 DBMET03538 0.074 0.065 DBMET03219 | DBMET03538 | |
| 0.013 | 0.091 | 0.028 | LFA antagonist | 0.028 0.02 DBMET03219 | DBMET03219 | |
| 0.079 | 0.158 | 0.107 | Alkaline phosphatase inhibitor | 0.107 0.104 DBMET03219 | DBMET03219 | |
| 0.019 | 0.1 | 0.043 | Ceramide glucosyltransferase inhibitor | 0.043 0.013 DBMET03538 | DBMET03538 | |
| 0.01 | 0.092 | 0.022 | Beta 1 adrenoreceptor agonist | 0.022 0.017 DBMET03219 | DBMET03219 | |
| 0.111 | 0.193 | 0.198 | Lipocortins synthesis antagonist | 0.198 0.058 DBMET03219 | DBMET03219 | |
| 0.031 | 0.113 | 0.051 | Factor IXa inhibitor | 0.051 0.036 DBMET03219 | DBMET03219 | |
| 0.048 | 0.13 | 0.069 | Beta 2 adrenoreceptor agonist | 0.069 0.02 DBMET03538 | DBMET03538 | |
| 0.02 | 0.103 | 0.055 | Factor XIa inhibitor | 0.055 0.015 DBMET03219 | DBMET03219 | |
| 0.145 | 0.228 | 0.226 | Hypoxia-inducible factor 1 alpha inhibitor | 0.226 0.123 DBMET03538 0.205 0.146 DBMET03219 | DBMET03538 | |
| 0.007 | 0.09 | 0.025 | Kainate receptor 3 antagonist | 0.025 0.006 DBMET03219 | DBMET03219 | |
| 0.045 | 0.129 | 0.108 | Ornithine decarboxylase inhibitor | 0.108 0.036 DBMET03219 | DBMET03219 | |
| 0.107 | 0.193 | 0.201 | Insulin sensitizer | 0.145 0.14 DBMET03538 0.201 0.072 DBMET03219 | DBMET03219 | |
| 0.021 | 0.109 | 0.038 | NMDA receptor subunit 3B antagonist | 0.038 0.037 DBMET03219 | DBMET03219 | |
| 0.066 | 0.16 | 0.124 | Interleukin 12 antagonist | 0.124 0.025 DBMET03538 | DBMET03538 | |
| 0.044 | 0.14 | 0.084 | HIV-1 integrase inhibitor | 0.084 0.035 DBMET03219 | DBMET03219 | |
| 0.085 | 0.181 | 0.17 | Phospholipase A2 inhibitor | 0.17 0.059 DBMET03219 | DBMET03219 | |
| 0.064 | 0.162 | 0.093 | Mucolytic | 0.093 0.088 DBMET03538 0.093 0.089 DBMET03219 | DBMET03219 | |
| 0.063 | 0.163 | 0.134 | AMP-activated protein kinase stimulant | 0.09 0.086 DBMET03538 0.134 0.038 DBMET03219 | DBMET03219 | |
| 0.027 | 0.128 | 0.051 | Alpha-mannosidase inhibitor | 0.051 0.041 DBMET03538 | DBMET03538 | |
| 0.039 | 0.143 | 0.088 | Histone deacetylase stimulant | 0.088 0.037 DBMET03219 | DBMET03219 | |
| 0.039 | 0.143 | 0.088 | Histone deacetylase SIRT1 stimulant | 0.088 0.037 DBMET03219 | DBMET03219 | |
| 0.012 | 0.116 | 0.054 | NMDA 2D receptor antagonist | 0.054 0.006 DBMET03219 | DBMET03219 | |
| 0.017 | 0.123 | 0.045 | RNA-directed RNA polymerase inhibitor | 0.045 0.015 DBMET03219 | DBMET03219 | |
| 0.042 | 0.149 | 0.08 | NMDA receptor antagonist | 0.08 0.065 DBMET03219 | DBMET03219 | |
| 0.033 | 0.14 | 0.083 | Carbonic anhydrase XIII inhibitor | 0.083 0.048 DBMET03219 | DBMET03219 | |
| 0.019 | 0.128 | 0.041 | Mannosidase inhibitor | 0.041 0.039 DBMET03538 | DBMET03538 | |
| 0.015 | 0.134 | 0.041 | Phosphorylase inhibitor | 0.041 0.036 DBMET03219 | DBMET03219 | |
| 0.098 | 0.219 | 0.144 | Non-steroidal antiinflammatory agent | 0.144 0.123 DBMET03219 | DBMET03219 | |
| 0.104 | 0.226 | 0.174 | Spasmolytic | 0.174 0.142 DBMET03538 0.173 0.143 DBMET03219 | DBMET03538 | |
| 0.008 | 0.131 | 0.028 | Kainate receptor 4 antagonist | 0.028 0.015 DBMET03219 | DBMET03219 | |
| 0.028 | 0.157 | 0.046 | Beta adrenoreceptor agonist | 0.046 0.03 DBMET03538 | DBMET03538 | |
| 0.04 | 0.174 | 0.159 | Topoisomerase I inhibitor | 0.159 0.038 DBMET03538 | DBMET03538 | |
| 0.006 | 0.142 | 0.026 | Somatostatin 5 antagonist | 0.026 0.025 DBMET03219 | DBMET03219 | |
| 0.007 | 0.143 | 0.056 | Retinoid X gamma receptor agonist | 0.056 0.005 DBMET03219 | DBMET03219 | |
| 0.025 | 0.167 | 0.064 | Phosphodiesterase III inhibitor | 0.064 0.048 DBMET03538 | DBMET03538 | |
| 0.033 | 0.177 | 0.052 | DNA helicase inhibitor | 0.052 0.044 DBMET03219 | DBMET03219 | |
| 0.006 | 0.163 | 0.038 | Retinoid X beta receptor agonist | 0.038 0.006 DBMET03219 | DBMET03219 | |
| 0.037 | 0.195 | 0.103 | Protein kinase (CK2) alpha inhibitor | 0.103 0.074 DBMET03219 | DBMET03219 | |
| 0.09 | 0.249 | 0.163 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.163 0.051 DBMET03219 | DBMET03219 | |
| 0.036 | 0.199 | 0.087 | Adrenaline agonist | 0.087 0.048 DBMET03538 | DBMET03538 | |
| 0.005 | 0.169 | 0.032 | Kainate receptor 5 antagonist | 0.032 0.009 DBMET03219 | DBMET03219 | |
| 0.031 | 0.199 | 0.097 | Protein kinase (CK2) inhibitor | 0.097 0.067 DBMET03219 | DBMET03219 | |
| 0.008 | 0.185 | 0.033 | Factor XI inhibitor | 0.033 0.026 DBMET03219 | DBMET03219 | |
| 0.1 | 0.28 | 0.126 | CC chemokine 6 receptor antagonist | 0.126 0.087 DBMET03219 | DBMET03219 | |
| 0.004 | 0.185 | 0.021 | Prostaglandin EP1 antagonist | 0.021 0.013 DBMET03219 | DBMET03219 | |
| 0.025 | 0.214 | 0.048 | Autotaxin inhibitor | 0.048 0.046 DBMET03219 | DBMET03219 | |
| 0.015 | 0.21 | 0.099 | Plasminogen activator inhibitor antagonist | 0.099 0.01 DBMET03219 | DBMET03219 | |
| 0.101 | 0.301 | 0.138 | Cyclin-dependent kinase 3 inhibitor | 0.138 0.13 DBMET03538 | DBMET03538 | |
| 0.061 | 0.276 | 0.153 | MAP3K9 inhibitor | 0.153 0.055 DBMET03538 | DBMET03538 | |
| 0.044 | 0.262 | 0.125 | Thrombolytic | 0.125 0.104 DBMET03219 | DBMET03219 | |
| 0.036 | 0.256 | 0.086 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.086 0.055 DBMET03219 | DBMET03219 | |
| 0.079 | 0.301 | 0.284 | Vasodilator | 0.218 0.091 DBMET03538 0.284 0.054 DBMET03219 | DBMET03219 | |
| 0.055 | 0.28 | 0.154 | Dual specificity phosphatase 3 inhibitor | 0.154 0.093 DBMET03219 | DBMET03219 | |
| 0.068 | 0.294 | 0.174 | Immunostimulant | 0.174 0.137 DBMET03538 | DBMET03538 | |
| 0.008 | 0.24 | 0.034 | Retinoid X gamma receptor antagonist | 0.034 0.008 DBMET03219 | DBMET03219 | |
| 0.129 | 0.362 | 0.342 | Interleukin 2 agonist | 0.342 0.049 DBMET03538 0.214 0.166 DBMET03219 | DBMET03538 | |
| 0.092 | 0.328 | 0.189 | Growth factor agonist | 0.189 0.075 DBMET03538 | DBMET03538 | |
| 0.111 | 0.355 | 0.263 | Sodium/bile acid cotransporter inhibitor | 0.263 0.115 DBMET03219 | DBMET03219 | |
| 0.053 | 0.308 | 0.146 | Dual specificity phosphatase inhibitor | 0.146 0.099 DBMET03219 | DBMET03219 | |
| 0.034 | 0.291 | 0.143 | Uric acid excretion stimulant | 0.143 0.026 DBMET03219 | DBMET03219 | |
| 0.062 | 0.32 | 0.165 | Platelet adhesion inhibitor | 0.165 0.091 DBMET03538 0.14 0.117 DBMET03219 | DBMET03538 | |
| 0.029 | 0.293 | 0.07 | Adenine nucleotide translocase inhibitor | 0.07 0.015 DBMET03219 | DBMET03219 | |
| 0.008 | 0.277 | 0.027 | Retinoic acid gamma receptor agonist | 0.027 0.009 DBMET03219 | DBMET03219 | |
| 0.008 | 0.284 | 0.076 | Prostaglandin E2 antagonist | 0.076 0.021 DBMET03219 | DBMET03219 | |
| 0.006 | 0.283 | 0.025 | Retinoic acid beta receptor agonist | 0.025 0.008 DBMET03219 | DBMET03219 | |
| 0.026 | 0.313 | 0.109 | M17 leucyl aminopeptidase inhibitor | 0.109 0.089 DBMET03219 | DBMET03219 | |
| 0.011 | 0.307 | 0.061 | Retinoic acid alpha receptor agonist | 0.061 0.009 DBMET03219 | DBMET03219 | |
| 0.122 | 0.42 | 0.455 | Cyclophilin D inhibitor | 0.343 0.127 DBMET03538 0.455 0.065 DBMET03219 | DBMET03219 | |
| 0.006 | 0.317 | 0.037 | Retinoic acid receptor agonist | 0.037 0.007 DBMET03219 | DBMET03219 | |
| 0.008 | 0.32 | 0.052 | Prostaglandin antagonist | 0.052 0.038 DBMET03219 | DBMET03219 | |
| 0.036 | 0.359 | 0.061 | Prolactin release inhibitor | 0.061 0.048 DBMET03538 | DBMET03538 | |
| 0.008 | 0.336 | 0.027 | Purinergic P2Y14 antagonist | 0.027 0.025 DBMET03219 | DBMET03219 | |
| 0.125 | 0.467 | 0.283 | Antiinflammatory | 0.277 0.237 DBMET03538 0.283 0.231 DBMET03219 | DBMET03219 | |
| 0.003 | 0.358 | 0.012 | Retinoic acid receptor gamma antagonist | 0.012 0.007 DBMET03219 | DBMET03219 | |
| 0.002 | 0.359 | 0.014 | Retinoic acid beta receptor antagonist | 0.014 0.006 DBMET03219 | DBMET03219 | |
| 0.076 | 0.452 | 0.226 | Immunomodulator | 0.226 0.136 DBMET03538 | DBMET03538 | |
| 0.003 | 0.38 | 0.026 | Retinoic acid alpha receptor antagonist | 0.026 0.009 DBMET03219 | DBMET03219 | |
| 0.039 | 0.419 | 0.15 | Platelet antagonist | 0.15 0.145 DBMET03219 | DBMET03219 | |
| 0.003 | 0.398 | 0.023 | Retinoic acid receptor antagonist | 0.023 0.009 DBMET03219 | DBMET03219 | |
| 0.005 | 0.401 | 0.096 | Nicotinic acid receptor 2 agonist | 0.096 0.006 DBMET03219 | DBMET03219 | |
| 0.016 | 0.415 | 0.068 | Prostaglandin F2 alpha antagonist | 0.068 0.034 DBMET03219 | DBMET03219 | |
| 0.059 | 0.476 | 0.223 | Hypoglycemic | 0.223 0.094 DBMET03219 | DBMET03219 | |
| 0.014 | 0.445 | 0.036 | Glutamate (mGluR8) antagonist | 0.036 0.025 DBMET03219 | DBMET03219 | |
| 0.021 | 0.455 | 0.132 | Mcl-1 antagonist | 0.132 0.11 DBMET03219 | DBMET03219 | |
| 0.031 | 0.553 | 0.078 | Transcription factor NF kappa B stimulant | 0.078 0.074 DBMET03538 | DBMET03538 | |
| 0.016 | 0.604 | 0.156 | Hypolipemic | 0.156 0.131 DBMET03219 | DBMET03219 | |
| 0.007 | 0.599 | 0.044 | Neuraminidase (Influenza A) inhibitor | 0.044 0.035 DBMET03219 | DBMET03219 | |
| 0.014 | 0.638 | 0.047 | Factor III inhibitor | 0.047 0.042 DBMET03219 | DBMET03219 | |
| 0.026 | 0.651 | 0.093 | ABCA1 expression enhancer | 0.093 0.06 DBMET03219 | DBMET03219 | |
| 0.005 | 0.72 | 0.065 | Neuraminidase (influenza) inhibitor | 0.065 0.042 DBMET03219 | DBMET03219 | |
| 0.004 | 0.77 | 0.055 | Neuraminidase inhibitor | 0.055 0.051 DBMET03219 | DBMET03219 | |
| 0.005 | 0.788 | 0.12 | Protein-tyrosine phosphatase inhibitor | 0.12 0.113 DBMET03219 | DBMET03219 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |